Explore

Trendline Trendline
Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference Highlighting Cancer Treatment Advances

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference Highlighting Cancer Treatment Advances

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference Highlighting Cancer Treatment Advances
Trendline Trendline
Max Planck Institute Study Reveals BET Inhibitors' Differential Impact on BRD2 and BRD4

Max Planck Institute Study Reveals BET Inhibitors' Differential Impact on BRD2 and BRD4

Max Planck Institute Study Reveals BET Inhibitors' Differential Impact on BRD2 and BRD4
Trendline Trendline
ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals

ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals

ImmunityBio Reports Significant Revenue Growth and Expands ANKTIVA Approvals
Trendline Trendline
Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Stoke Therapeutics to Present at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances
Trendline Trendline
AI in Life Sciences Market to Transform Drug Development and Precision Medicine

AI in Life Sciences Market to Transform Drug Development and Precision Medicine

AI in Life Sciences Market to Transform Drug Development and Precision Medicine
Trendline Trendline
Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development
Trendline Trendline
Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition